Sigachi Industries Ltd

This key approval is for its upcoming manufacturing facility dedicated to Bulk Drugs, Drug Intermediates, and Specialty Chemicals, including Active Pharmaceutical Ingredients (APIs), to be established at Orvakal in Kurnool District, Andhra Pradesh. This strategic project is proposed over 25.09 acres at Plot No. A-10, Guttapadu-Orvakal Node. The facility falls under Category B1, aligned with Schedule 5(f) of the EIA Notification, 2006, applicable to the Synthetic Organic Chemicals sector. The Environmental Clearance (EC) process for the upcoming facility is set to begin on 15 July 2025, with project development activities scheduled to commence from 1 August 2025. The project is expected to be instrumental in enhancing the company's API manufacturing capacity and strengthening its global presence. It will support the expansion of the product pipeline across regulated and semi-regulated markets, while also establishing a strategically located facility with strong export potential. Additionally, the project aligns with the 'Make in India' initiative, promoting world-class infrastructure and sustainable manufacturing practices. Commenting on this development, Amit Raj Sinha, managing director and CEO of Sigachi Industries stated - 'This is a significant milestone in our journey to become a vertically integrated pharmaceutical manufacturing company. The Orvakal project will anchor our next phase of growth in APIs and specialty chemicals, helping us create scalable, sustainable, and compliant operations for global markets. At Sigachi, we are strategically positioning ourselves to cater to increasing global demand by building capacity closer to key markets and regulatory jurisdictions. The new facility will not only strengthen our product supply chain but also enable faster commercialization, seamless tech transfers, and enhanced responsiveness to evolving customer requirements.' Telangana-based Sigachi Industries is engaged in the manufacturing of microcrystalline cellulose (MCC), which is widely used in the pharmaceutical, food, beverage, cosmetic, and paint industries. The most common uses of MCC are in vitamin supplements and tablets. It also acts as a bulking agent in food production. MCC is produced from refined wood pulp, which is imported by the company. The company's consolidated net profit tanked 11.8% to Rs 13.27 crore despite 23.1% rise in revenue from operations to Rs 128.20 crore in Q4 FY25 over Q4 FY24.Powered by Capital Market - Live

Sigachi Industries has received the Terms of Reference (ToR) from the State Environment Impact Assessment Authority (SEIAA), Andhra Pradesh for its upcoming Bulk Drugs, Drug Intermediates, and Specialty Chemicals facility at Orvakal, Kurnool District. This strategic project is proposed over 25.09 acres at Plot No. A-10, Guttapadu-Orvakal Node. The facility falls under Category B1, aligned with Schedule 5(f) of the EIA Notification, 2006, applicable to the Synthetic Organic Chemicals sector. With the Terms of Reference now in place, the Environmental Clearance (EC) process is set to commence from 15th July 2025, followed by project development activities beginning from 1st August 2025. Powered by Capital Market - Live

Net profit of Sigachi Industries declined 11.77% to Rs 13.27 crore in the quarter ended March 2025 as against Rs 15.04 crore during the previous quarter ended March 2024. Sales rose 23.12% to Rs 128.20 crore in the quarter ended March 2025 as against Rs 104.13 crore during the previous quarter ended March 2024. For the full year,net profit rose 21.65% to Rs 69.56 crore in the year ended March 2025 as against Rs 57.18 crore during the previous year ended March 2024. Sales rose 22.38% to Rs 488.24 crore in the year ended March 2025 as against Rs 398.96 crore during the previous year ended March 2024. ParticularsQuarter EndedYear EndedMar. 2025Mar. 2024% Var.Mar. 2025Mar. 2024% Var. Sales128.20104.13 23 488.24398.96 22 OPM %22.2815.69 -20.4819.21 - PBDT27.4120.70 32 108.0980.57 34 PBT22.6717.21 32 92.3269.77 32 NP13.2715.04 -12 69.5657.18 22 Powered by Capital Market - Live

Sigachi Industries announced that the Board of Directors of the Company at its meeting held on 30 May 2025, inter alia, have recommended the final dividend of Rs 0.1 per equity Share (i.e. 10%) , subject to the approval of the shareholders.Powered by Capital Market - Live

Sigachi Industries will hold a meeting of the Board of Directors of the Company on 30 May 2025.Powered by Capital Market - Live

Sigachi Industries announced that Trimax Biosciences, a Sigachi Group Company has successfully achieved the Certificate of Suitability (CEP) for 'Metformin Hydrochloride' from European Directorate for the Quality of Medicines & Health Care (EDQM). This milestone paves the way for Trimax to export this crucial Active Pharmaceutical Ingredient (API) to Europe and other CEP-accepting markets, further strengthening Sigachi's presence in highly regulated pharmaceutical markets. Powered by Capital Market - Live

Headquartered in the Czech Republic, Respilon is an innovation-driven nanofiber R&D company. Sigachi and Respilon will collaborate to develop, manufacture, and commercialize drug delivery solutions based on Respilon's proprietary NUENEX nanofiber technology. The two entities would focus on the development of Invisible Patch and Powder-based pharmaceutical delivery formats. The collaboration includes developing commercialization strategies for relevant APIs and formulations, leveraging nanofiber encapsulation technology. Amit Raj Sinha, managing director and CEO of Sigachi Industries, said: Partnering with Respilon aligns perfectly with our vision to deliver next-generation pharmaceutical solutions that improve therapeutic outcomes and elevate the patient experience. We are excited about the possibilities NUENEX technology offers to revolutionize drug delivery systems globally.' Telangana-based Sigachi Industries is engaged in the manufacturing of microcrystalline cellulose (MCC), which is widely used in the pharmaceutical, food, beverage, cosmetic, and paint industries. The most common uses of MCC are in vitamin supplements and tablets. It also acts as a bulking agent in food production. MCC is produced from refined wood pulp, which is imported by the company. The company reported 32.52% jump in consolidated net profit to Rs 21.35 crore in Q3 FY25 from Rs 16.11 crore posted in Q3 FY24. Revenue from operations grew by 25.66% to Rs 139.41 crore in Q3 FY25 from Rs 110.94 crore registered in Q3 FY24. The scrip rose 0.30% to currently trade at Rs 42.95 on the BSE. Powered by Capital Market - Live

 Sigachi MENA FZCO, a wholly owned subsidiary of Sigachi Industries, has signed a Memorandum of Understanding (MoU) with Respilon, an innovation-driven nanofiber R&D company headquartered in the Czech Republic. This partnership marks a significant milestone in Sigachi's strategy to expand into advanced drug delivery technologies. Sigachi and Respilon will collaborate to develop, manufacture, and commercialize drug delivery solutions based on Respilon's proprietary NUENEX' nanofiber technology. The collaboration includes developing commercialization strategies for relevant APIs and formulations, leveraging nanofiber encapsulation technology.Powered by Capital Market - Live

Sigachi Industries will hold a meeting of the Board of Directors of the Company on 8 February 2025.Powered by Capital Market - Live

Sigachi Industries is establishing a state-of-the-art R&D Center in Hyderabad to enhance its Research and Development (R&D) capabilities. This strategic initiative involves an investment of up to USD 1 million with the objective of bringing its critical API developments and Analytical Efforts under one roof. Powered by Capital Market - Live